A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Highlands Oncology Group, Springdale, Arkansas +25 locations
Conditions: Advanced Breast Cancer
Register for Updates
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217
Recruiting
The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT target... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/06/2025
Locations: Stanford University, Palo Alto, California +11 locations
Conditions: Metastatic Neuroendocrine Prostate Cancer
Register for Updates
Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
NCT06063538
Recruiting
The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing cardiac arterial bypass grafting (CABG) or valve surgery.
Gender:
ALL
Ages:
Between 20 years and 85 years
Trial Updated:
08/06/2025
Locations: The University of Chicago, Chicago, Illinois
Conditions: Atrial Fibrillation, Post-Op Complication
Register for Updates
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
NCT06668584
Recruiting
The goal of this clinical research study is to learn about the safety and tolerability of giving olutasidenib to patients with IDH1-mutated myeloid malignancies as maintenance therapy after they receive a stem cell transplant.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Myeloid Malignancies
Register for Updates
SPI-1005 in Adults Receiving Cochlear Implant
NCT06340633
Recruiting
The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear. The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005? The clinical trial will also measure the effects of SPI-1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hearing Loss, Cochlear Trauma
Register for Updates
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
NCT06547554
Recruiting
A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/06/2025
Locations: Minneapolis Clinic, Minneapolis, Minnesota
Conditions: Bacterial Infections
Register for Updates
Exercise Facilitation of Adolescent Fear Extinction, Frontolimbic Circuitry, and Endocannabinoids
NCT06297278
Recruiting
Anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. Recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. This study will test whether a behavioral intervention, acute exer... Read More
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
08/06/2025
Locations: Tolan Park Medical Building, Detroit, Michigan
Conditions: Adolescence
Register for Updates
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
NCT06593314
Recruiting
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure, Diabetes
Register for Updates
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +36 locations
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
NCT06687980
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Center for Dermatology Clinical Research- Site Number : 8400226, Fremont, California +56 locations
Conditions: Lichen Simplex Chronicus
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: Teva Investigational Site 12087, Phoenix, Arizona +87 locations
Conditions: Asthma
Register for Updates
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
NCT06569667
Recruiting
Black and Latinx people who use opioids are disproportionately impacted by opioid overdose deaths. The proposed study assesses the efficacy of an open source, multimodal artificial intelligence-driven texting tool combined with peer recovery coach-supported text contact that delivers social services, stigma reduction, health habitus, and patient navigation content addressing social determinants of health to enhance receipt of buprenorphine in primary care among emergency department-enrolled Blac... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/06/2025
Locations: NYC Health + Hospitals, Bronx, New York
Conditions: Opioid Use Disorder
Register for Updates